Table 2.

Patient’s characteristic. Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance status; K-RAS = Kirsten rat sarcoma viral oncogene homologue; N-RAS = Neuroblastoma RAS viral oncogene homologue B1; Anti-VEGF: anti-vascular endothelial growth factor antibodies; Anti-EGFR: anti-epidermal growth factor antibodies.

	Low CD44 Expression	High CD44 Expression
Gender M F	28 (54.9%) 23 (45.1%)	11 (78.6%) 3 (21.4%)
Age <70 ≥70	39 (76.5%) 12 (23.5%)	8 (57.2%) 6 (42.8%)
Stage at diagnosis I–III IV	20 (39.2%) 31 (60.8%)	1 (7.1%) 13 (92.9%)
CDX-2 Positive Negative	48 (94.1%) 3 (5.9%)	11 (78.6%) 3 (21.4%)
Site of primary tumour Sx Dx	38 (74.5%) 13 (25.5%)	10 (71.4%) 4 (28.6%)
Surgery of the primary tumour Yes No	46 (90.2%) 5 (9.8%)	7 (50%) 7 (50%)
Tumour Grade Good–moderate Poor	41 (80.4%) 10 (19.6%)	6 (42.8%) 8 (57.2%)
Metastases sites Single site Multiple site	19 (37.3%) 32 (62.7%)	3 (21.4%) 11 (78.6%)
Liver Metastases Yes No	34 (66.7%) 17 (33.3%)	12 (85.7%) 2 (14.3%)
Peritoneal Metastases Yes No	16 (31.4%) 35 (68.6%)	6 (42.9%) 8 (57.1%)
K-RAS/N-RAS mutational status Wild type Mutant	27 (52.9%) 24 (47.1%)	7 (50%) 7 (50%)
B-RAF mutational status Wild type Mutant	46 (90.2%) 5 (9.8%)	9 (64.3%) 5 (35.7%)
First-line chemotherapy Monotherapy Doublet Triplet	6 (11.8%) 42 (82.3%) 3 (5.9%)	2 (14.3%) 8 (57.1%) 4 (28.6%)
First-line biological drug Anti-VEGF Anti-EGFR None	32 (62.8%) 7 (13.7%) 12 (23.5%)	9 (64.3%) 2 (14.3%) 3 (21.4%)
Second-line chemotherapy Monotherapy Doublet None	3 (5.9%) 32 (62.7%) 16 (31.4%)	1 (7.1%) 7 (50%) 6 (42.9%)
Second-line biological drug Anti-VEGF Anti-EGFR None	22 (43.1%) - 29 (56.9%)	5 (35.7%) 1 (7.1%) 8 (57.2%)